Genomics Reporting Implementation Guide
2.0.0 - trial-use

This page is part of the Genetic Reporting Implementation Guide (v2.0.0: STU 2) based on FHIR R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

: PGxRecEx04 - XML Representation

Raw xml | Download



<Task xmlns="http://hl7.org/fhir">
  <id value="PGxRecEx04"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative</b></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource "PGxRecEx04" </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-followup-recommendation.html">Followup Recommendation</a></p></div><p><b>status</b>: requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: Decrease dose <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://loinc.org/">LOINC</a>#LA26422-8)</span></p><p><b>description</b>: For escitalopram, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment or select an alternate drug not predominantly metabolized by CYP2C19. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations.</p><p><b>for</b>: <a href="Patient-CGPatientExample01.html">Patient/CGPatientExample01</a> " EVERYMAN"</p><p><b>reasonReference</b>: <a href="Observation-TxImp04.html">Observation/TxImp04: Poor metabolizer</a></p></div>
  </text>
  <status value="requested"/>
  <intent value="proposal"/>
  <code>
    <coding>
      <system value="http://loinc.org"/>
      <code value="LA26422-8"/>
      <display value="Decrease dose"/>
    </coding>
  </code>
  <description
               value="For escitalopram, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment or select an alternate drug not predominantly metabolized by CYP2C19. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations."/>
  <for>
    <reference value="Patient/CGPatientExample01"/>
  </for>
  <reasonReference>
    <reference value="Observation/TxImp04"/>
    <display value="Poor metabolizer"/>
  </reasonReference>
</Task>